Lv4
788 积分 2022-09-21 加入
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
15天前
已关闭
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
15天前
已关闭
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
15天前
已完结
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
16天前
已完结
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
17天前
已完结
The Moving Target: Cis -Mutation–Driven Resistance to p53-Y220C Reactivator
1个月前
已完结
Insights on Future Directions in Cancer Research from the 2026 AACR NextGen Stars
2个月前
已完结
The Moving Target: Cis-Mutation–Driven Resistance to p53-Y220C Reactivator
2个月前
已完结
Cancer Throughlines: 25 Years after First Approval, ADCs Continue to Pick up Steam
2个月前
已关闭